Table 2.
Descriptive Statistics for Pre- v Postperiod Cohorts
| Statistic | Preperiod Cohort (diagnosed between January and December 2002) |
Postperiod Cohort (diagnosed between June 2004 and May 2005) |
P | ||
|---|---|---|---|---|---|
| Mean | SD | Mean | SD | ||
| No. of patients | 2,644 | 3,231 | |||
| Male, % | 53.2 | 53.1 | .9783 | ||
| Age at diagnosis, years | 56.0 | 11.2 | 54.9 | 9.9 | < .001 |
| Follow-up time, months | 10.0 | 2.9 | 10.3 | 2.7 | < .001 |
| Costs up to 1 year of follow-up, $ | |||||
| Total | 60,586 | 52,385 | 107,994 | 85,162 | < .001 |
| Inpatient | 26,109 | 38,092 | 36,106 | 57,424 | < .001 |
| Inpatient/skilled nursing facility | 219 | 2,731 | 120 | 1,586 | .0834 |
| Pharmacy | 5,197 | 7,273 | 7,506 | 11,910 | < .001 |
| Emergency room | 199 | 578 | 754 | 4,388 | < .001 |
| Home health | 696 | 2,020 | 1,444 | 4,462 | < .001 |
| Office visits | 3,952 | 3,752 | 7,057 | 10,131 | < .001 |
| Laboratory | 892 | 1,080 | 1,185 | 1,353 | < .001 |
| X-ray | 4,199 | 6,269 | 5,933 | 7,436 | < .001 |
| Chemotherapy administration | 7,621 | 13,761 | 26,174 | 34,911 | < .001 |
| Other outpatient | 11,503 | 18,901 | 21,713 | 28,718 | < .001 |
| Utilization* | |||||
| No. of hospital stays | 1.4 | 1.4 | 1.5 | 1.4 | .0478 |
| Length of hospital stay, days | 8.5 | 7.5 | 8.1 | 6.9 | .0064 |
| No. of hospital days | 12.0 | 15.5 | 12.0 | 15.2 | .9305 |
| Comorbid conditions, % | |||||
| Myocardial infarction | 2.6 | 2.7 | .7723 | ||
| Congestive heart failure | 7.6 | 8.0 | .5765 | ||
| Peripheral vascular disease | 4.2 | 4.6 | .5212 | ||
| Cerebrovascular disease | 4.8 | 4.9 | .9188 | ||
| Dementia | 0.6 | 1.2 | .0225 | ||
| Chronic pulmonary disease | 10.0 | 12.6 | .0017 | ||
| Ulcer | 1.9 | 2.2 | .3526 | ||
| Mild liver disease | 1.0 | 1.2 | .4354 | ||
| Diabetes | 16.5 | 16.2 | .7635 | ||
| Diabetes with organ damage | 2.2 | 2.0 | .5799 | ||
| Hemiplegia | 1.1 | 0.7 | .1539 | ||
| Moderate/severe renal disease | 3.1 | 3.4 | .5569 | ||
| Moderate/severe liver disease | 1.2 | 1.5 | .2992 | ||
| Metastatic solid tumor | 65.3 | 65.8 | .7235 | ||
| AIDS | 0.2 | 0.3 | .4199 | ||
| Rheumatologic disease | 1.0 | 1.1 | .6822 | ||
| First-line chemotherapy regimen, % | < .001 | ||||
| FU | 18.2 | 23.1 | |||
| FU/LV | 54.4 | 24.7 | |||
| IFL or FOLFIRI | 20.7 | 7.0 | |||
| Capecitabine | 6.4 | 8.8 | |||
| Capecitabine/irinotecan | 0.1 | 0.0 | |||
| FOLFOX | 0.2 | 32.8 | |||
| Capecitabine/oxaliplatin | 0.0 | 0.8 | |||
| FU/LV + bevacizumab | 0.0 | 0.4 | |||
| IFL + bevacizumab | 0.0 | 0.8 | |||
| Other biologic | 0.0 | 1.4 | |||
| Other | 0.0 | 0.2 | |||
| Second-line therapy, %† | 39.0 | 42.0 | .0028 | ||
| Resection, % | 53.0 | 64.0 | < .001 | ||
NOTE. Data adapted from LifeLink Health Plans Claims Database.
Abbreviations: FOLFIRI, fluorouracil plus irinotecan; FOLFOX, fluorouracil/leucovorin with oxaliplatin; FU, fluorouracil; IFL, fluorouracil plus irinotecan; LV, leucovorin; SD, standard deviation.
*
All utilization measures represent use during the first year after diagnosis.
†
Second-line therapy is defined as chemotherapy 6 weeks to 3 months after initial treatment.